All In Biotech

Drug Trial Radar · NCT04183166

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

A Randomized Phase I/II Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy.

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

80

Actual

Start

Dec 12, 2019

Primary completion

Dec 30, 2027

Study completion Dec 30, 2031

Sponsor

Lead sponsor
TransgeneIndustry
Sponsor type
Industry
First posted
Dec 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

  • TG4050Drug

    Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Safety and tolerability (Adverse Event reported per CTCAE v5)Time frame: Up to 2 Years.
  2. Phase I/II: Disease-Free SurvivalTime frame: Up to 2 years.

Locations

14 sites in 4 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Hôpital Saint André - CHU de Bordeaux

    Bordeaux, France

  • Hôpital de la Timone

    Marseille, France

  • Institut Curie

    Paris, France

  • IUCT Toulouse

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • Hospital Universitari Vall d Hebrón

    Barcelona, Spain

  • Institut Català d Oncologia - Hospital Duran i Reynals

    Barcelona, Spain

  • Hospital Clínico San Carlos

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Regional Universitario de Málaga - Hospital Civil

    Málaga, Spain

  • Complejo Hospitalario Universitario de Santiago

    Santiago de Compostela, Spain

  • NHS Clatterbridge Cancer Center

    Liverpool, United Kingdom

  • Aintree University Hospital NHS Fondation Trust

    Liverpool, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.